PRESS RELEASE published on 03/18/2025 at 18:30, 1 year 7 months ago Oxurion ondertekent intentieverklaring voor de voorgenomen overname van een CRO gespecialiseerd in biometrie Oxurion NV kondigt intentie aan om meerderheidsbelang in Franse CRO over te nemen, gespecialiseerd in klinisch databeheer en biometrische analyse. Strategische uitbreiding voor farmaceutische sector Overname CRO Oxurion NV Biometrische Analyse Klinisch Databeheer
BRIEF published on 03/18/2025 at 18:05, 1 year 7 months ago Oxurion Announces Transparency Updates Regarding Atlas Special Opportunities Atlas Special Opportunities Oxurion Belgian Legislation Transparency Notifications Voting Securities
BRIEF published on 03/18/2025 at 18:05, 1 year 7 months ago Oxurion annonce des mises à jour de transparence concernant les opportunités spéciales d'Atlas Oxurion Opportunités Spéciales Atlas Notifications De Transparence Titres Avec Droit De Vote Législation Belge
PRESS RELEASE published on 03/18/2025 at 18:00, 1 year 7 months ago Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC Oxurion NV receives transparency notifications from Atlas Special Opportunities, LLC regarding selling of voting securities, crossing thresholds. Developing ophthalmic therapies for retinal disease Atlas Special Opportunities Ophthalmic Therapies Oxurion NV Retinal Disease Transparency Notifications
PRESS RELEASE published on 03/18/2025 at 18:00, 1 year 7 months ago Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities LLC Oxurion NV ontvangt meerdere transparantiekennisgevingen van Atlas Special Opportunities LLC over verkoop van aandelen conform Belgische wetgeving. Lees meer op www.oxurion.com Atlas Special Opportunities LLC Transparantiekennisgevingen Aandelen Oxurion NV Belgische Wetgeving
BRIEF published on 03/04/2025 at 19:05, 1 year 8 months ago Oxurion Extends Financing Agreement With Atlas Convertible Bonds Market Capitalization Atlas Special Opportunities Oxurion Financing Program
BRIEF published on 03/04/2025 at 19:05, 1 year 8 months ago Oxurion prolonge son accord de financement avec Atlas Obligations Convertibles Capitalisation Boursière Oxurion Opportunités Spéciales Atlas Programme De Financement
PRESS RELEASE published on 03/04/2025 at 19:00, 1 year 8 months ago Oxurion Extends Its Financing Program Oxurion NV signs third amendment to convertible bond subscription agreement with Atlas Special Opportunities II, LLC, extending issuance period and clarifying maturity terms Amendment Convertible Bond Oxurion NV Atlas Special Opportunities II Financing Terms
PRESS RELEASE published on 03/04/2025 at 19:00, 1 year 8 months ago Oxurion verlengt haar financieringsprogramma Oxurion NV verlengt financieringsprogramma en past voorwaarden aan in overeenkomst met Atlas Special Opportunities. Meer informatie beschikbaar op oxurion.com Atlas Special Opportunities Oxurion NV Financieringsprogramma Biofarmaceutisch Bedrijf Obligatie
BRIEF published on 02/14/2025 at 19:05, 1 year 8 months ago Oxurion Enhances Board with Nelly Souleymane's Appointment Innovation Board Changes Biopharmaceutical Diversity Oxurion
Published on 11/10/2026 at 02:45, 4 hours 20 minutes ago Presentation to Zurich Precious Metals Summit
Published on 11/09/2026 at 23:10, 7 hours 55 minutes ago Ur-Energy Reports Third Quarter 2026 Results
Published on 11/09/2026 at 23:00, 8 hours 5 minutes ago LNG Energy Group Announces Issuance of Third Partial Revocation Order and Proposed Shares-for-Debt Settlement
Published on 11/09/2026 at 22:32, 8 hours 33 minutes ago Announces Extension for Closing of Private Placement of Convertible Promissory Notes
Published on 11/09/2026 at 22:15, 8 hours 50 minutes ago Goldcliff Announces Closing of the Second and Final Tranche of its "LIFE" Offering and Completion of Drilling at Kettle Valley
Published on 11/10/2026 at 06:55, 10 minutes ago EEII AG: EEII AG et Haute Capital Partners SA concluent un accord d’exclusivité
Published on 11/10/2026 at 06:55, 10 minutes ago EEII AG: EEII AG and Haute Capital Partners SA Enter into Exclusivity Agreement
Published on 11/10/2026 at 06:55, 10 minutes ago Significant increase in earnings as at 30 September 2026: FFO I guidance for 2026 raised; initial guidance for 2027 points to further growth; LTV remains low
Published on 11/10/2026 at 06:00, 1 hour 5 minutes ago Ad hoc announcement pursuant to Art. 53 LR 10 November 2026
Published on 11/10/2026 at 07:00, 5 minutes ago bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
Published on 11/09/2026 at 18:30, 12 hours 35 minutes ago Air Liquide has successfully issued a CHF 390 million multi-tranche bond
Published on 11/09/2026 at 18:30, 12 hours 35 minutes ago Air Liquide a réalisé avec succès une émission obligataire multi-tranches de 390 millions de CHF
Published on 11/09/2026 at 17:45, 13 hours 20 minutes ago Déclaration hebdomadaire de rachat d'actions
